Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Terminated · Phase 1 · NCT04465487
Conditions: Squamous Cell Carcinoma of Head and Neck
At a glance
- Research payments reported, 2025
- $204,407
- U.S. investigators named
- 5
- Sites paid
- 6
- Planned or actual enrollment
- 38
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN6569 (drug), Cemiplimab (drug)
- Dates
- Started 2020-10-05; completion 2025-02-07
- Results posted
- Not yet
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab may help shrink certain types of cancer. The study is also looking at: * Side effects that may be experienced by people taking REGN6569 alone and with cemiplimab * How REGN6569 and cemiplimab work in the body * How much REGN6569 and cemiplimab is in your blood * To see if REGN6569 can lower the number of Treg cells in tumors * To see if REGN6569 and cemiplimab can shrink tumors when given together
From ClinicalTrials.gov, last updated 2025-02-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $204,407 in research payments for this study in 2025 (43 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omid Hamid, M.D. Hematology & Oncology · Santa Monica, CA
- Aixa Soyano Muller, MD Hematology & Oncology · Tampa, FL
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Paul L. Swiecicki, MD Medical Oncology · Ann Arbor, MI
- Douglas R. Adkins, MD Medical Oncology · Saint Louis, MO
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Michigan Health System, MI $71,598
- Cedars Sinai Medical Care Foundation $53,074
- Washington University School of Medicine $26,800
- Start Midwest $23,919
- Moffitt Cancer Center $20,140
- Start Midwest LLC $8,876
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.